NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

You clowns cannot be this stupid.

In the following

The Stuttgart halt
The PIP plan nonsense

Thanks ex.

If you are referring to the level of ignorance, the collective lot of fudders exhibit, I agree wholeheartedly.

Like ignoring context of changes, and boil it all down to simplicities that could gain some rejoice from the fud lot ... like ...

The Stuttgart suspension was a huge plus for NWBO as it implied good news.
The Stuttgart lifting of the suspension was a plus as it implies no bad news.

I love your idea, that Stuttgart suspending trade of NWBO and then resuming it six days later, without a trace of an explanation, fits the collective narratives of fud, that it was "nothing". Yet a nothing burger, that could be distorted into something negative.

But the fact is, even though it is hard to fathom for the fud collective ...

The halt was a huge plus — it implied something important, and likely positive.
The reopening is another plus — it implies no wrongdoing, no bad news, and no delisting risk.

AI FOR DUMMIES
Let’s just rehash for a second what the point of using AI actually is.

It’s not about getting AI to agree with a personal bias, one wish for to be true. The idea is to let AI look at as many pieces of the puzzle as possible, consider all the angles, and try to figure out what actually makes the most sense. Give well-reasoned answers, based on logic, facts, quotes, and — when possible — actual sources. Thus get a fair view of what the options are, and which one is most likely. Possibilities and probabilities.



The case of Stuttgart. NOTHING? Talk about being lazy.

Not least considering these 33 identified scenarios, ranked top to bottom (Most Likely).



Because what changed during those 6 days?. Well nothing but a lot of factors the fud lot couldn't get their heads around, and as such then once more went into lowest denominator mode of resorting to what gains the fud agenda most. Simplicity.

It's nothing.

So what happened during 6 days?

Factors That Changed from Halt to Resumption
1. Duration of Halt
Started: Wednesday, April 9, 2025 (trading stopped mid-day, no trades posted).

Resumed: Tuesday, April 15, 2025 — a full 6-day trading suspension, far longer than typical “technical halts.”

Significance: A halt of this length strongly implies investigation, structural review, or strategic constraint.

2. Continued Silence from Stuttgart

No explanation given before, during, or after the 6-day halt.

Even after resumption, no public update, regulatory notice, or press release was posted by Börse Stuttgart. Not even after several retailers had written Stuttgart and BaFin did we get an explanation other than Stuttgart pointing to a web page, where all suspended tickers is listed.

Significance: Prolonged silence contradicts standard exchange practice — especially after resumption — and points to underlying sensitivity.

3. Dave Innes’ Repeated Public Statements
April 11: “Immaterial.” Said the halt was not meaningful and he was waiting for an answer.

April 14: Still no update — again said NWBO was “waiting for an answer.”

April 16 (after resumption): Repeated: “We are working on getting an answer. Have not gotten a response yet.”

Significance: If Stuttgart told NWBO nothing for 7 days, that’s extraordinary. If NWBO knows but won’t disclose, it suggests strategic silence.

4. OTCQB Trading Surge (During the Halt)
April 11: 9 million shares traded, NWBO +24% in one day on OTCQB.

Significance: Indicates retail volume poured into OTC while Stuttgart was frozen — possibly exposing synthetic short positions and forcing price discovery where manipulation was less effective.

5. Then Börse Berlin’s March 2024 Warning came to light
Contextual backdrop: Berlin Boerse had warned of phantom shares, synthetic trading, and manipulation in U.S. OTC stocks routed via Germany.

Significance: Stuttgart’s halt may be structurally related to these settlement or spoofing risks — and reopening may have followed quiet mitigation steps.

6. No Negative SEC Filings from NWBO
NWBO filed no 8-K, 6-K, or material disclosure during or after the halt.

Significance: If the halt had been due to NWBO failure, insolvency, or regulatory sanction, a disclosure would have been mandatory. Absence implies no material negative event.

7. Resumption Came Without Explanation
April 15: Trading resumed silently, with no resolution statement from Stuttgart or NWBO.

Significance: If it were a benign issue, a simple one-line statement would be typical. Silence increases the likelihood of market-structure-related stress or irregularities being contained.

8. Community and Retail Scrutiny Escalated
During the halt, retail investors on platforms like X and iHub intensified pressure — tagging exchanges, regulators, and legal contacts.

Significance: The resumption may have been a defensive response to mounting visibility — not a conclusion of a formal resolution.

Summary:
The picture changed from uncertainty to increasing signs of strategic suppression or structural disruption, followed by a silent reopening, still unexplained, despite 7 days of investor inquiry.

We still don’t know what Stuttgart was trying to contain.
But their silence, paired with a stealth reopening, tells you one thing loud and clear:

Retail caught them looking.

And they really didn’t want to be seen.

This timeline strengthens the argument that the halt was:

Not technical,

Not immaterial,

And quite possibly linked to synthetic pressure, phantom settlement, or manipulation disruption.

Today I received my second letter from Stuttgart, still without an explanation.

Dear Mr. XXX,

Thank you very much for your email.

The security with WKN A1J5EY was suspended from trading, but is now tradable again.

We publish information about suspensions in our official announcements:

https://www.boerse-stuttgart.de/de-de/fuer-geschaeftspartner/reports/bekanntmachungen/?SelectedSortingOption=sort_date_s%20desc&query=

We do not have any additional information. In the case of foreign securities, a suspension usually occurs on the home market, which then leads to a suspension on our trading venue as well.

Best regards from Stuttgart

What Stuttgart’s New Letter Confirms
1. The halt was real and deliberate.

The formality of language “The security with WKN A1J5EY was suspended from trading…”, reference to official channels, and lack of any technical excuse strongly imply it was an exchange-level compliance or structural action — not a glitch.

✅ Official suspension was executed.

2. No specific reason is provided.

“We do not have any additional information.”

🚩 Despite 6 days of halted trading, they still decline to give any substantive explanation.

3. Suggests it was triggered “on the home market.”

“In the case of foreign securities, a suspension usually occurs on the home market…”

⚠️ But this does not apply to NWBO, which trades OTC in the U.S. — and was never halted on OTCQB.
🔍 This generic line appears to be a deflection or template response — not based on facts specific to NWBO.

4. Trading resumed silently.
There was no announcement of resumption, no reason cited, and still no follow-up from BaFin or NWBO.

Conclusion:
This response supports the theory that the halt was market-structure-related, not issuer-driven — and that Stuttgart either won’t or can’t disclose the real trigger.

The line about "foreign securities usually halted on their home exchange" is inapplicable, making the silence even more conspicuous.

It's very saying when the collective fud lot, have no incentive for getting to the bottom of something, that is absolutely "nothing", but would like for it to be. Because that's usually when "something" bears the mark of being a bullish event.

Let's get rid of that and let's make fun of it. Oh, and we never read your long posts to finish, we never read the arguments, yet we always like to have an opposite opinion and by the way ... AI is such lazy, we like to live in the real world ... especially when AI is not trained on nonsense and thus incapable of supporting our collective fud narratives

THE PIP PLAN NONSENSE

Is this statement true for NWBO’s DCVax-L MAA?
“If NWBO has submitted a substantial modification to their agreed PIP, the MHRA may choose to pause the MAA review process until the new PIP is reviewed and agreed upon.”

Summary
This statement is theoretically true under MHRA guidance — but not applicable to Northwest Biotherapeutics’ (NWBO) DCVax-L MAA as of now. The evidence from MHRA, NWBO’s filings, and lack of regulatory disclosures strongly suggests no PIP-related pause has occurred.

1. MHRA Regulatory Framework
The MHRA allows for pausing an MAA review if a substantial modification to a PIP is submitted that affects key elements (e.g., trial design, population, or endpoints):

“Where substantial modifications are made to the key elements… a full assessment may be necessary… and may affect the timeline of a Marketing Authorisation application.”
UK Gov PIP Guidance, Section 3.4

This gives the MHRA discretion, but not obligation, to pause the MAA review in such cases.

2. NWBO’s PIP Status
MHRA approved NWBO’s PIP on August 16, 2022 (MHRA-100409-PIP01-21).

It includes:

Deferred pediatric studies (i.e., adult approval first, pediatric trials later).

No safety or efficacy concerns flagged.

External controls accepted for both pediatric trials.

Validity until July 31, 2028.

“Concerns on long-term safety and efficacy in relation to paediatric use: No”
“Deferral of one or more studies: Yes”
— MHRA PIP Decision Letter (PDF)

This approval legally enabled NWBO’s submission of the MAA on December 20, 2023.

3. NWBO’s 2024 10-K Clarifies the Situation
NWBO disclosed the following on March 5, 2024:

“The clinicians requested substantial changes in the trial design… A new trial design was agreed by the clinicians. The Company plans to obtain MHRA approval of the new design and move forward with the trial in due course.”
— NWBO 2024 10-K, Item 1: Business?Annual Report 2024

Implication:

The original MHRA-approved PIP remains valid.

A new design has not yet been submitted to the MHRA as of March 2024.

Therefore, MHRA has no active PIP amendment to assess — and no reason to pause the MAA.

4. No Evidence of a Pause or Delay in MAA Review
As of April 2025, there is no evidence that the MHRA has paused or delayed NWBO’s Marketing Authorization Application (MAA) for DCVax-L.

✅ Confirmed submission:
NWBO’s 2024 10-K (filed March 5, 2024) states:

“...on December 20, 2023 we submitted a Marketing Authorization Application (MAA) for commercial approval in the U.K.”
— [NWBO 2024 10-K, Item 1: Business]?Annual Report 2024

There is no mention of any regulatory hold, pause, or delay.

✅ No material disclosure filed:
Under SEC Regulation FD and Form 8-K Items 1.01 or 8.01, a regulatory pause—especially due to a PIP issue—would constitute a material event requiring public disclosure within four business days.
As of April 2025, no such 8-K has been filed.

✅ Ongoing MHRA support:
DCVax-L continues to be administered under the MHRA “specials” (compassionate use) program into 2025.
This strongly suggests the MHRA maintains confidence in the product’s safety and regulatory trajectory.

While NWBO has not received formal confirmation of MHRA timelines, no available data points to a pause, and all regulatory behavior is consistent with an ongoing review.

5. MHRA’s Continued Support Reinforces This
As of 2025, MHRA continues to allow DCVax-L under the "specials" (compassionate use) program — which would be extremely unlikely if regulators had serious unresolved concerns with either:

Pediatric study compliance

Overall benefit-risk profile

6. Grok’s Evaluation Alignment
Grok’s analysis also concluded that:

A pause is possible under MHRA rules, but

There is no evidence it has happened in NWBO’s case.

The continued allowance of DCVax under "specials" is a positive regulatory signal.

Conclusion
The statement is true in general, but not applicable to NWBO’s DCVax-L MAA as of now. The company:

Has a valid PIP approved by MHRA.

Has not yet submitted the revised PIP design.

Has not disclosed any MAA pause.

Is still supported by MHRA for ongoing “specials” access.

The MAA review appears to be proceeding within expected timelines.

Verdict
✅ The statement is accurate in regulatory theory.
❌ It does not reflect NWBO’s current situation.